Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditisJohn R. Power, Ellen Warner, Steven M. Ewer et al.|Archives of cardiovascular diseases|2022Cited by 38
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Clinical Cancer Research|2021Cited by 19
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre StudyL. Vitek, G. Quéreux, Thomas Goronflot et al.|Acta Dermato Venereologica|2024Cited by 9
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Caroline Robert, Alexander Christopher Jonathan Van Akkooi, Caroline Dutriaux et al.|Journal of Clinical Oncology|2024Cited by 8